Adherence to immunomodulatory drugs in patients with multiple myeloma
Open Access
- 27 March 2019
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 14 (3) , e0214446
Abstract
Immunomodulatory drugs (thalidomide, lenalidomide and pomalidomide; IMID) are widely used in the treatment of multiple myeloma patients. To date, few data are available on IMID adherence in multiple myeloma patients. The aim of our study was to evaluate IMID adherence and to compare two indirect methods to measure IMID adherence in multiple myeloma patients: a specific questionnaire and the medication possession ratio (MPR). Another aim was to explore this specific questionnaire for the assessment of IMID adherence in multiple myeloma patients. All consecutive multiple myeloma patients, with at least two consecutive dispensations of thalidomide, lenalidomide or pomalidomide in our hospital were included in this prospective study. IMID adherence was measured using a specific questionnaire and the medication possession ratio. Relationship between the questionnaire scores and variables of interest was evaluated by multiple linear regression with a robust variance estimator. Sixty-three patients were included in our study. The mean questionnaire score was 8.2±1.2 and the mean medication possession ratio value was 0.97±0.06. A total of 76% of patients were considered adherent according to the questionnaire (i.e. score ≥ 8), 94% according to the medication possession ratio (i.e. MPR ≥ 0.90), and 70% according to the questionnaire and the medication possession ratio. No statistically significant linear association was observed between the questionnaire score and any variables of interest including medication possession ratio. All Cronbach’s alpha were relatively low (range 0.0342–0.2443), showing a low correlation of the different questions with the questionnaire score. Our study is the first prospective study evaluating IMID adherence in multiple myeloma patients in real life. The high adherence to IMIDs reported here, regardless of the drug, is encouraging considering the efficacy, toxicity and elevated cost of IMIDs. The specific questionnaire should be used with caution to evaluate IMID adherence.Keywords
This publication has 22 references indexed in Scilit:
- Do patients on oral chemotherapy have sufficient knowledge for optimal adherence? A mixed methods studyEuropean Journal of Cancer Care, 2015
- Treatment for patients with newly diagnosed multiple myeloma in 2015Blood Reviews, 2015
- Financial toxicity in insured patients with multiple myeloma: a cross-sectional pilot studyThe Lancet Haematology, 2015
- Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012International Journal of Cancer, 2014
- Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trialThe Lancet Oncology, 2013
- Adherence to oral antineoplastic agents by cancer patients: definition and literature reviewEuropean Journal of Cancer Care, 2013
- Comment évaluer l’adhésion médicamenteuse ? Le point sur les méthodesAnnales Pharmaceutiques Françaises, 2013
- The economic consequences of noncompliance in cardiovascular disease and related conditions: a literature reviewInternational Journal Of Clinical Practice, 2008
- International Staging System for Multiple MyelomaJournal of Clinical Oncology, 2005
- Concurrent and Predictive Validity of a Self-reported Measure of Medication AdherenceMedical Care, 1986